UY25794A1 - Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a - Google Patents
Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2aInfo
- Publication number
- UY25794A1 UY25794A1 UY25794A UY25794A UY25794A1 UY 25794 A1 UY25794 A1 UY 25794A1 UY 25794 A UY25794 A UY 25794A UY 25794 A UY25794 A UY 25794A UY 25794 A1 UY25794 A1 UY 25794A1
- Authority
- UY
- Uruguay
- Prior art keywords
- preparation
- adenine
- adenosine
- procedure
- receptor agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Otolaryngology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Abstract
La presente invención proporciona un procedimiento para la preparación de compuestos derivados de adenina de fórmula (I), en la que: R1 es alquilo o ciclopropilmetilo; R2 es fenil-alquileno o naftil-alquileno; n es 1 ó 2; A es NRa, NRaC(O), NRaC(O)NRa, NRaC(O)O, OC(O)NRa, C(O)NRa, NRaSO2, SO2NRa, O, S o SO2; Ra es H, alquilo o bencilo; R3 es un grupo de fórmula -(CH2)p-Rp-B; p es 0, 1 ó 2; Rp es un enlace, alquileno, cicloalquileno, fenileno o naftileno; B es i) H, -NRbRb, RbRbN-alquileno, -ORb, -COORb, -OCORb, -SO2Rb, -CN, -SO2NRbRb, -NRbCORb, -NRbSO2Rb o -CONRbRb, en los que Rb son iguales o diferentes y se seleccionan entre H, alquilo, fenilo y bencilo; ii) un grupo heterocíclico mono- o bicíclico; iii) azetidinilo, pirrolidinilo, piperidinilo, piperazinilo o morfolinilo; a una sal o un solvato farmacéuticamente aceptables de los mismos. Dichos compuestos tienen actividad agonista de receptor A2a de adenosina y, por tanto, pueden utilizarse como agentes anti-inflamatorios en el tratamiento de enfermedades del tracto respiratorio, entre otras. Ej. no limitante: (2R,3R,4S,5S)-2-[2-(aminometil)-6-[(2,2-difeniletil)amino]-9H-purin-9-il]-5-(metoximetil)tetrahidro-3,4-furanodiol
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9822702.8A GB9822702D0 (en) | 1998-10-16 | 1998-10-16 | Compounds |
GBGB9825383.4A GB9825383D0 (en) | 1998-11-19 | 1998-11-19 | Compounds |
GBGB9908931.0A GB9908931D0 (en) | 1999-04-19 | 1999-04-19 | Compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
UY25794A1 true UY25794A1 (es) | 2000-08-21 |
Family
ID=27269521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY25794A UY25794A1 (es) | 1998-10-16 | 1999-11-11 | Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a |
Country Status (16)
Country | Link |
---|---|
US (1) | US6326359B1 (es) |
EP (1) | EP1121372B1 (es) |
JP (1) | JP3602445B2 (es) |
AT (1) | ATE331726T1 (es) |
AU (1) | AU5879299A (es) |
BR (1) | BR9914526A (es) |
CA (1) | CA2347512C (es) |
CO (1) | CO5450244A1 (es) |
DE (1) | DE69932173T2 (es) |
ES (1) | ES2264826T3 (es) |
MA (1) | MA26699A1 (es) |
PA (1) | PA8484201A1 (es) |
PE (1) | PE20001225A1 (es) |
TN (1) | TNSN99191A1 (es) |
UY (1) | UY25794A1 (es) |
WO (1) | WO2000023457A1 (es) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6514949B1 (en) | 1994-07-11 | 2003-02-04 | University Of Virginia Patent Foundation | Method compositions for treating the inflammatory response |
US6232297B1 (en) | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
US7378400B2 (en) | 1999-02-01 | 2008-05-27 | University Of Virginia Patent Foundation | Method to reduce an inflammatory response from arthritis |
US7427606B2 (en) | 1999-02-01 | 2008-09-23 | University Of Virginia Patent Foundation | Method to reduce inflammatory response in transplanted tissue |
GB9924363D0 (en) * | 1999-10-14 | 1999-12-15 | Pfizer Central Res | Purine derivatives |
GB9924361D0 (en) | 1999-10-14 | 1999-12-15 | Pfizer Ltd | Purine derivatives |
GB0003960D0 (en) * | 2000-02-18 | 2000-04-12 | Pfizer Ltd | Purine derivatives |
US6627785B1 (en) * | 2000-02-29 | 2003-09-30 | Virginia Commwealth University | Wound dressings with protease-lowering activity |
GB0014048D0 (en) * | 2000-06-06 | 2000-08-02 | Pfizer Ltd | Purine derivatives |
US6753322B2 (en) * | 2000-06-06 | 2004-06-22 | Pfizer Inc | 2-aminocarbonyl-9H-purine derivatives |
TWI227240B (en) * | 2000-06-06 | 2005-02-01 | Pfizer | 2-aminocarbonyl-9H-purine derivatives |
GB0015727D0 (en) * | 2000-06-27 | 2000-08-16 | Pfizer Ltd | Purine derivatives |
US6921753B2 (en) | 2000-06-27 | 2005-07-26 | Pfizer Inc | Purine derivatives |
GB0022695D0 (en) * | 2000-09-15 | 2000-11-01 | Pfizer Ltd | Purine Derivatives |
US6670334B2 (en) | 2001-01-05 | 2003-12-30 | University Of Virginia Patent Foundation | Method and compositions for treating the inflammatory response |
US6852738B2 (en) | 2001-01-30 | 2005-02-08 | Merck & Co., Inc. | Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
GB2372742A (en) * | 2001-03-03 | 2002-09-04 | Univ Leiden | C2,5'-Disubstituted and N6,C2,5'-trisubstituted adenosine derivatives and their different uses |
WO2002072067A2 (en) * | 2001-03-12 | 2002-09-19 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
WO2002096462A1 (en) * | 2001-05-25 | 2002-12-05 | Pfizer Inc. | An adenosine a2a receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases |
US20030013675A1 (en) * | 2001-05-25 | 2003-01-16 | Boehringer Ingelheim Pharma Kg | Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases |
CA2460911C (en) | 2001-10-01 | 2011-08-30 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
ATE381336T1 (de) * | 2002-04-10 | 2008-01-15 | Univ Virginia | Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
US20050033044A1 (en) * | 2003-05-19 | 2005-02-10 | Bristol-Myers Squibb Pharma Company | Methods for preparing 2-alkynyladenosine derivatives |
US20050059664A1 (en) * | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Novel methods for identifying improved, non-sedating alpha-2 agonists |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
TWI346109B (en) * | 2004-04-30 | 2011-08-01 | Otsuka Pharma Co Ltd | 4-amino-5-cyanopyrimidine derivatives |
US20050277615A1 (en) * | 2004-05-17 | 2005-12-15 | Can-Fite Biopharma Ltd. | Pharmaceutical compositions having anti-inflammatory activity |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
US7423144B2 (en) | 2004-05-26 | 2008-09-09 | Inotek Pharmaceuticals Corporation | Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof |
WO2006028618A1 (en) | 2004-08-02 | 2006-03-16 | University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity |
US7605143B2 (en) * | 2004-08-02 | 2009-10-20 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs with modified 5′-ribose groups having A2A agonist activity |
US7442687B2 (en) | 2004-08-02 | 2008-10-28 | The University Of Virginia Patent Foundation | 2-polycyclic propynyl adenosine analogs having A2A agonist activity |
EP1802316B1 (en) * | 2004-09-20 | 2011-11-02 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
JP2008527003A (ja) * | 2005-01-12 | 2008-07-24 | キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド | 喘息又は気管支痙攣の既往歴を有する患者における心筋機能不全を検出する方法 |
GB0500785D0 (en) | 2005-01-14 | 2005-02-23 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
ATE497960T1 (de) * | 2005-10-13 | 2011-02-15 | Cv Therapeutics Inc | A1-adenosinrezeptoragonisten |
KR20080049113A (ko) | 2005-10-21 | 2008-06-03 | 노파르티스 아게 | Il-13에 대항한 인간 항체 및 치료적 용도 |
AU2006320578B2 (en) * | 2005-11-30 | 2013-01-31 | Inotek Pharmaceuticals Corporation | Purine derivatives and methods of use thereof |
US8795730B2 (en) * | 2006-01-31 | 2014-08-05 | David John Vachon | Compositions and methods for promoting the healing of tissue of multicellular organisms |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
WO2007120972A2 (en) | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
ES2440317T3 (es) | 2006-04-21 | 2014-01-28 | Novartis Ag | Derivados de purina para su uso como agonistas del receptor de adenosina A2A |
GB0607950D0 (en) | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607945D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
GB0607948D0 (en) * | 2006-04-21 | 2006-05-31 | Novartis Ag | Organic compounds |
US8188063B2 (en) | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
EP1889846A1 (en) | 2006-07-13 | 2008-02-20 | Novartis AG | Purine derivatives as A2a agonists |
EP1903044A1 (en) | 2006-09-14 | 2008-03-26 | Novartis AG | Adenosine Derivatives as A2A Receptor Agonists |
ATE502943T1 (de) | 2006-09-29 | 2011-04-15 | Novartis Ag | Pyrazolopyrimidine als pi3k-lipidkinasehemmer |
RU2009120389A (ru) | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Гетероциклические соединения в качестве противовоспалительных агентов |
US7897737B2 (en) | 2006-12-05 | 2011-03-01 | Lasergen, Inc. | 3′-OH unblocked, nucleotides and nucleosides, base modified with photocleavable, terminating groups and methods for their use in DNA sequencing |
WO2009061516A1 (en) * | 2007-11-08 | 2009-05-14 | New York University School Of Medicine | Medical implants containing adenosine receptor agonists and methods for inhibiting medical implant loosening |
US8058259B2 (en) | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
WO2009087224A1 (en) | 2008-01-11 | 2009-07-16 | Novartis Ag | Pyrimidines as kinase inhibitors |
BRPI0915173B8 (pt) * | 2008-06-11 | 2021-05-25 | Agilent Technologies Inc | compostos de nucleotídeos e nucleosídeos e método de sequenciamento de um ácido nucleico-alvo |
SI2391366T1 (sl) | 2009-01-29 | 2013-01-31 | Novartis Ag | Substituirani benzimidazoli za zdravljenje astrocitomov |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
CA2770873A1 (en) | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
SG178454A1 (en) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Heterocyclic compounds and uses thereof |
IN2012DN01453A (es) | 2009-08-20 | 2015-06-05 | Novartis Ag | |
CN102711771B (zh) | 2010-01-11 | 2016-05-18 | 伊诺泰克制药公司 | 降低眼压的组合、试剂盒和方法 |
CN102933593A (zh) | 2010-03-26 | 2013-02-13 | 伊诺泰克制药公司 | 使用n6-环戊基腺苷(cpa)、cpa衍生物或其前药降低人眼内压的方法 |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン, エルエルシー | 複素環化合物およびその使用 |
MA34969B1 (fr) | 2011-02-25 | 2014-03-01 | Irm Llc | Composes et compositions en tant qu inibiteurs de trk |
CA2848809A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines as c-met tyrosine kinase |
CA2856803A1 (en) | 2011-11-23 | 2013-05-30 | Intellikine, Llc | Enhanced treatment regimens using mtor inhibitors |
EA027109B1 (ru) | 2012-01-26 | 2017-06-30 | Инотек Фармасьютикалс Корпорейшн | Безводные полиморфы [(2r,3s,4r,5r)-5-(6-(циклопентиламино)-9h-пурин-9-ил)-3,4-дигидрокситетрагидрофуран-2-ил]метилнитрата и способы их получения |
EP3964513A1 (en) | 2012-04-03 | 2022-03-09 | Novartis AG | Combination products with tyrosine kinase inhibitors and their use |
WO2014063134A1 (en) | 2012-10-19 | 2014-04-24 | New York University | Methods for inhibiting osteolysis |
MX2015013234A (es) | 2013-03-15 | 2016-04-15 | Inotek Pharmaceuticals Corp | Formulaciones oftalmicas. |
WO2014151147A1 (en) | 2013-03-15 | 2014-09-25 | Intellikine, Llc | Combination of kinase inhibitors and uses thereof |
TW201605450A (zh) | 2013-12-03 | 2016-02-16 | 諾華公司 | Mdm2抑制劑與BRAF抑制劑之組合及其用途 |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
AU2015294889B2 (en) | 2014-07-31 | 2018-03-15 | Novartis Ag | Combination therapy |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988003147A1 (en) * | 1986-10-31 | 1988-05-05 | Warner-Lambert Company | Selected n6-substituted adenosines having selective a2 binding activity |
GB2264948B (en) * | 1992-03-13 | 1996-10-16 | Merck & Co Inc | Human adenosine receptors |
US5877180A (en) * | 1994-07-11 | 1999-03-02 | University Of Virginia Patent Foundation | Method for treating inflammatory diseases with A2a adenosine receptor agonists |
US5859019A (en) * | 1997-03-07 | 1999-01-12 | Trustees Of The University Of Pennsylvania | Methods for protecting against cardiac ischemia by administering adenosine A2a receptor antagonists |
CA2289731A1 (en) * | 1997-05-09 | 1998-11-12 | The United States Of America, Represented By The Secretary, Department O F Health And Human Services | Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists |
AU2108299A (en) * | 1998-01-08 | 1999-07-26 | University Of Virginia Patent Foundation | A2A adenosine receptor agonists |
GB9813535D0 (en) * | 1998-06-23 | 1998-08-19 | Glaxo Group Ltd | Chemical compounds |
US6232297B1 (en) * | 1999-02-01 | 2001-05-15 | University Of Virginia Patent Foundation | Methods and compositions for treating inflammatory response |
GB9913932D0 (en) * | 1999-06-15 | 1999-08-18 | Pfizer Ltd | Purine derivatives |
EP1194441B1 (en) * | 1999-06-22 | 2003-10-22 | Cv Therapeutics, Inc. | A2a receptor agonists |
US6214807B1 (en) * | 1999-06-22 | 2001-04-10 | Cv Therapeutics, Inc. | C-pyrazole 2A A receptor agonists |
US6180615B1 (en) * | 1999-06-22 | 2001-01-30 | Cv Therapeutics, Inc. | Propargyl phenyl ether A2A receptor agonists |
-
1999
- 1999-10-05 EP EP99946382A patent/EP1121372B1/en not_active Expired - Lifetime
- 1999-10-05 CA CA002347512A patent/CA2347512C/en not_active Expired - Fee Related
- 1999-10-05 AU AU58792/99A patent/AU5879299A/en not_active Abandoned
- 1999-10-05 JP JP2000577183A patent/JP3602445B2/ja not_active Expired - Fee Related
- 1999-10-05 DE DE69932173T patent/DE69932173T2/de not_active Expired - Fee Related
- 1999-10-05 AT AT99946382T patent/ATE331726T1/de not_active IP Right Cessation
- 1999-10-05 BR BR9914526-0A patent/BR9914526A/pt not_active Application Discontinuation
- 1999-10-05 WO PCT/IB1999/001629 patent/WO2000023457A1/en active IP Right Grant
- 1999-10-05 ES ES99946382T patent/ES2264826T3/es not_active Expired - Lifetime
- 1999-10-13 TN TNTNSN99191A patent/TNSN99191A1/fr unknown
- 1999-10-13 MA MA25818A patent/MA26699A1/fr unknown
- 1999-10-14 PA PA19998484201A patent/PA8484201A1/es unknown
- 1999-10-14 CO CO99065444A patent/CO5450244A1/es not_active Application Discontinuation
- 1999-10-15 PE PE1999001043A patent/PE20001225A1/es not_active Application Discontinuation
- 1999-10-15 US US09/419,482 patent/US6326359B1/en not_active Expired - Fee Related
- 1999-11-11 UY UY25794A patent/UY25794A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
BR9914526A (pt) | 2001-07-03 |
DE69932173T2 (de) | 2007-06-06 |
PE20001225A1 (es) | 2000-11-07 |
DE69932173D1 (de) | 2006-08-10 |
TNSN99191A1 (fr) | 2005-11-10 |
CA2347512C (en) | 2005-12-06 |
JP3602445B2 (ja) | 2004-12-15 |
ATE331726T1 (de) | 2006-07-15 |
CA2347512A1 (en) | 2000-04-27 |
EP1121372A1 (en) | 2001-08-08 |
US6326359B1 (en) | 2001-12-04 |
WO2000023457A1 (en) | 2000-04-27 |
MA26699A1 (fr) | 2004-12-20 |
PA8484201A1 (es) | 2000-09-29 |
CO5450244A1 (es) | 2004-10-29 |
AU5879299A (en) | 2000-05-08 |
JP2002527524A (ja) | 2002-08-27 |
EP1121372B1 (en) | 2006-06-28 |
ES2264826T3 (es) | 2007-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY25794A1 (es) | Procedimiento para la preparacion de compuestos derivados de adeninas, que son agonistas del receptor de la adenosina a2a | |
BG106569A (en) | Purine derivatives | |
AP2001002361A0 (en) | Purine derivatives. | |
BG106567A (en) | Purine derivatives | |
AP2002002598A0 (en) | Purine derivatives. | |
BG107171A (en) | Purine derivatives | |
AR020442A1 (es) | Agonistas de 5ht2serotonergicos para el tratamiento de glaucoma | |
ECSP003682A (es) | Compuestos para el tratamiento de la isquemia | |
DK0760811T3 (da) | Imidazolderivater som histaminreceptor H3-modulatorer | |
AP2001002287A0 (en) | Purine derivatives. | |
DK0725782T3 (da) | A1-adenosin-receptor-agonister og antiagonister | |
AR024138A1 (es) | Inhibidores de la proliferacion celular | |
ECSP045146A (es) | Moléculas pequeñas para el tratamiento del crecimiento celular anormal | |
BRPI0511695A (pt) | agonistas de receptor (beta)2 adrenérgico diamina | |
BRPI0414634A (pt) | agonistas de receptor b2, adrenérgico de etilamino amino-substituìdo | |
AR024232A1 (es) | Bromhidrato de eletriptan monohidratado, composicion farmaceutica, su uso en la preparacion de medicamentos y procedimiento para su preparacion | |
IT1270612B (it) | Derivati eterociclo-condensatori di morfinoidi | |
IT1291278B1 (it) | Preparazione farmaceutica a base di nimesulide per uso topico | |
ES2175661T3 (es) | Derivados de la isoflavona, procedimientos para la preparacion de los mismos y composiciones farmaceuticas que los contienen. | |
BR0206844A (pt) | Uso de antagonistas do receptor gal3 para o tratamento de depressão e/ou ansiedade e compostos usados em tais métodos | |
MX9605687A (es) | Derivados de imidazol de anti(agonistas) del receptor h3 de la histamina. | |
UY27524A1 (es) | Epta-, octa-y nonapéptidos con actividad antingiogénica | |
IT1270611B (it) | Derivati eterociclo-condensati di morfinoidi |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ABAN | Application deemed to be withdrawn (no publication fee paid) |
Effective date: 20090512 |